Infection, Human Immunodeficiency Virus I Clinical Trial
Official title:
A Prospective Observational Cohort Study to Monitor and Compare the Occurrence of Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Dolutegravir (With and Without Abacavir) or Other Integrase Inhibitors (With or Without Abacavir)
Dolutegravir (DTG) is recommended for both treatment-naïve and treatment-experienced, HIV infected adults and paediatric subjects aged 12 years and older and weighing at least 40 kg. One case of suspected DTG hypersensitivity (HSR) reaction from among over 1500 subjects exposed to the drug at the time of submission in 4Q2012, has been identified; this subject experienced a diffuse maculopapular rash with fever and elevated liver enzymes. Isolated rash was uncommon in the DTG programme with less than 1% of clinical trial subjects experiencing treatment related rash. The pharmacovigilance strategy for DTG and DTG-containing products is to implement a post-marketing risk management program to further quantify the risk of HSR and compare it to that of other integrase inhibitors, and to possibly determine associated risk factors. In addition, the post-authorization safety study will monitor and compare hepatotoxicity and severe skin rash following initiation of DTG or other integrase inhibitor (raltegravir (RAL) or elvitegravir (EGV) based antiretroviral regimens (ARV). Further to be able to distinguish the above symptoms and reactions caused by DTG or the other integrase inhibitor regimen from that of abacavir (ABC), known to cause hypersensitivity reaction, the integrase inhibitor groups will be compared in combinations with and without ABC. This five year-long safety study will be conducted through collaboration with EuroSIDA, a well established prospective observational cohort study of more than 18,200 subjects followed in 107 hospitals in 31 European countries, plus Israel and Argentina. This is a five year-long non-interventional prospective cohort study nested within the EuroSIDA study. The study population will include HIV positive subjects over the age of 16 years from EuroSIDA clinical sites, who are new users of DTG or other integrase inhibitors with and without ABC. Following initiation of DTG with ABC based antiretroviral regimen or DTG without ABC or regimens containing other integrase inhibitors (RAL, EGV) with or without ABC or any other DTG based ARV regimen as monotherapy or two-drug regimens, the study will aim to a) Monitor and compare hypersensitivity reaction, b) Monitor and compare hepatotoxicity, and c) Monitor and compare severe skin rash among all subjects discontinuing DTG or other integrase inhibitor regimens for any reason.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00257621 -
GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults
|
Phase 2 | |
| Completed |
NCT01227824 -
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
|
Phase 3 | |
| Completed |
NCT01597648 -
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
|
Phase 1 | |
| Completed |
NCT01205243 -
ZIAGEN® Post-marketing Surveillance
|
||
| Withdrawn |
NCT01283100 -
A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
|
Phase 1 | |
| Completed |
NCT00450580 -
HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
|
Phase 3 | |
| Completed |
NCT00440947 -
Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection
|
Phase 3 | |
| Completed |
NCT00549198 -
KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects
|
Phase 4 | |
| Completed |
NCT00481390 -
Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients
|
N/A | |
| Completed |
NCT00242840 -
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
|
Phase 3 | |
| Terminated |
NCT00197145 -
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects
|
Phase 3 | |
| Completed |
NCT00089583 -
48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
|
Phase 2 | |
| Completed |
NCT00044577 -
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
|
Phase 3 | |
| Terminated |
NCT00104429 -
GW873140 In Combination With Combivir In HIV Infected Subjects
|
Phase 2 | |
| Completed |
NCT01263015 -
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
|
Phase 3 | |
| Terminated |
NCT00102778 -
GW873140 In Combination With Kaletra In HIV Infected Subjects
|
Phase 2 | |
| Completed |
NCT00094523 -
Fosamprenavir Versus Other Protease Inhibitors
|
Phase 3 | |
| Completed |
NCT00046176 -
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
|
Phase 3 | |
| Terminated |
NCT00242879 -
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
|
Phase 2 | |
| Completed |
NCT00082394 -
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
|
Phase 4 |